Given that the current overall outcome of AML patients remains relatively poor despite employing cytogenetic and molecular-risk stratification and precision medicine. Information considering only cytogenetics and single molecular aberrations are often utilized for therapy selection. Response for physician prescribed therapies (PPT) is predicted by the Cellworks Singula report using the novel Cellworks Omics Biology Model (CBM) to simulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells.